For two drugs with a branded product that had a large price increase, the market share of the related biosimilar or generic was higher among Medicaid MCOs not subject to preferred drug lists (PDLs) as compared to MCOs subject to PDLs and Medicaid FFS programs, according to a JMCP study.
Sponsored webinar that provided an overview of key pharmacist-specific considerations for biosimilars, including details of the approval process, considerations for appropriate use, and practices that mitigate inadvertent substitution and encourage accurate adverse event reporting.
AMCP webinar that provided an overview of the current state of biosimilars in the US, description of some barriers to utilization, discussion of real-world data and how stakeholders may use real-world evidence to inform treatment and coverage decisions, and an update on the efforts of BBCIC.
The Biologics and Biosimilars Collective Intelligence Consortium (BBCIC) was established to address anticipated needs for post-marketed evidence generation for novel biologics, their corresponding biosimilars and other related products.
AMCP CEO Blog: AMCP’s roughly 8,000 members work diligently every day to improve patient care through the optimized use of medicines. As an organization, we also take a leading role in developing improvements to the overall delivery of care, which is no easy task given the size and complexity of our health care system.
Press Release: From News&Views April 2019: The Biologics Price Competition and Innovation Act (BPCIA) of 2009 created an FDA approval pathway for biosimilars that aimed to expanded patient access to these more affordable therapies.